{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:55:09Z","timestamp":1780372509797,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.semarthrit.2023.152270","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:04:19Z","timestamp":1695920659000},"page":"152270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: A crossover trial"],"prefix":"10.1016","volume":"63","author":[{"given":"Glaxon","family":"Alex","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KC","family":"Shanoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delcey Rachel","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AS","family":"Sageer Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Reji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanabha D.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152270_bib0001","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0003","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0004","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respiratory Med"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00296-009-0966-8","article-title":"The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats","volume":"30","author":"Zheng","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0007","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/annrheumdis-2015-eular.3483","article-title":"SAT0442 mycophenolate mofetil (MMF) use in scleroderma patients with pulmonary hypertension: FVC, outcomes and survival- observations from the pulmonary hypertension recognition and outcomes in scleroderma (Pharos) cohort","volume":"74","author":"Saketkoo","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2023.152270_bib0008","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/rheumatology\/key151","article-title":"Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease","volume":"58","author":"Khanna","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0009","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-0012.2008.00892.x","article-title":"Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies","volume":"22","author":"Bunnapradist","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0010","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/rheumatology\/keq238","article-title":"Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil","volume":"49","author":"Schaier","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0011","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/bcp.12664","article-title":"No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study","volume":"80","author":"Rissling","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0012","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13075-020-02323-8","article-title":"Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation\u2014a prospective, observational study","volume":"22","author":"- Andr\u00e9asson","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0013","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/art.27495","article-title":"Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil","volume":"62","author":"Zahr","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0014","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1093\/ndt\/gfn360","article-title":"Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil","volume":"23","author":"Neumann","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0015","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0016","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00007691-199906000-00012","article-title":"A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma","volume":"21","author":"Svensson","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0017","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1177\/0091270011412968","article-title":"Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers","volume":"52","author":"Kees","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0018","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/j.transproceed.2010.09.047","article-title":"Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil","volume":"42","author":"Doesch","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0019","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","article-title":"Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial","volume":"86","author":"van Gelder","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0020","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0021","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/01.ASN.0000051598.12824.DA","article-title":"Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients","volume":"14","author":"Neumann","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0022","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1093\/ndt\/gfn360","article-title":"Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil","volume":"23","author":"Neumann","year":"2008","journal-title":"Nephrol, Dial, Transplant"},{"key":"10.1016\/j.semarthrit.2023.152270_bib0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/ndt\/gfy026","article-title":"The utility of trough mycophenolic acid levels for the management of lupus nephritis","volume":"34","author":"Pourafshar","year":"2019","journal-title":"Nephrol Dial Transplant"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:12:15Z","timestamp":1758733935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223001129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":23,"alternative-id":["S0049017223001129"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152270","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: A crossover trial","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152270"}}